The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy

European Journal of Cancer

Volumn 43, Issue 16, 2007, Pages 2330-2338

  Smith, Laura ^a   Lind, Michael J ^a   Drew, Philip J ^a   Cawkwell, Lynn ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Chemotherapy; Proteasome; Radiotherapy; Ubiquitin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; DOXORUBICIN; PROTEASOME; UBIQUITIN; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG INHIBITION; DRUG MECHANISM; ENZYME DEGRADATION; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 35448971525     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.07.023     Document Type: Article

References (75)

1. Dalton W.S. The proteasome. Semin Oncol 31 (2004) 3-9
2. Kuhlbrodt K., Mouysset J., and Hoppe T. Orchestra for assembly and fate of polyubiquitin chains. Essays Biochem 41 (2005) 1-14
3. Pickart C.M. Mechanisms underlying ubiquitination. Annu Rev Biochem 70 (2001) 503-533
4. Nijman S.M., Luna-Vargas M.P., Velds A., et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123 (2005) 773-786
5. Hoppe T. Multiubiquitylation by E4 enzymes: 'one size' doesn't fit all. Trends Biochem Sci 30 (2005) 183-187
6. Hochrainer K., and Lipp J. Ubiquitylation within signaling pathways in- and outside of inflammation. Thromb Haemost 97 (2007) 370-377
7. Wang X., Chen C.F., Baker P.R., Chen P.L., Kaiser P., and Huang L. Mass spectrometric characterization of the affinity-purified human 26S proteasome complex. Biochemistry 46 (2007) 3553-3565
8. Hirano Y., Hayashi H., Iemura S., et al. Cooperation of multiple chaperones required for the assembly of mammalian 20S proteasomes. Mol Cell 24 (2006) 977-984
9. Groll M., Bajorek M., Kohler A., et al. A gated channel into the proteasome core particle. Nat Struct Biol 7 (2000) 1062-1067
10. Rechsteiner M., and Hill C.P. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 15 (2005) 27-33
11. DeMartino G.N. Purification of PA700, the 19S regulatory complex of the 26S proteasome. Methods Enzymol 398 (2005) 295-306
12. Khan S., van den Broek M., Schwarz K., de Giuli R., Diener P.A., and Groettrup M. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol 167 (2001) 6859-6868
13. Ustrell V., Hoffmann L., Pratt G., and Rechsteiner M. PA200, a nuclear proteasome activator involved in DNA repair. EMBO J 21 (2003) 3516-3525
14. Tanahashi N., Murakami Y., Minami Y., Shimbara N., Hendil K.B., and Tanaka K. Hybrid proteasomes: induction by interferon-γ and contribution to ATP-dependent proteolysis. J Biol Chem 275 (2000) 14336-14345
15. Catley L., Tai Y.T., Chauhan D., and Anderson K.C. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Res Updates 8 (2005) 205-218
16. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
17. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 667-675
18. Demarchi F., and Brancolini C. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies. Drug Res Updates 8 (2005) 359-368
19. Bogner C., Peschel C., and Decker T. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma 47 (2006) 195-205
20. Milano A., Iaffaioli R.V., and Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours?. Eur J Cancer 43 (2007) 1125-1133
21. Cusack J.C., Liu R., Houston M., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61 (2001) 3535-3540
22. Russo S.M., Tepper J.E., Baldwin A.S., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 50 (2001) 183-193
23. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9 (2003) 1136-1144
24. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
25. Aghajanian C., Dizon D.S., Sabbatini P., Raizer J.J., Dupont J., and Spriggs D.R. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23 (2005) 5943-5949
26. Orlowski R.Z., Voorhees P.M., Garcia R.A., et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105 (2005) 3058-3065
27. Jagannath S., Richardson P.G., Barlogie B., et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91 (2006) 929-934
28. Usui T., Yoshida M., Honda A., Beppu T., and Horinouchi S. A K-252a-resistance gene, sks1+, encodes a protein similar to the Caenorhabditis elegans F37 A45 gene product and confers multidrug resistance in Schizosaccharomyces pombe. Gene 161 (1995) 93-96
29. Nagao K., Taguchi Y., Arioka M., et al. bfr1+, a novel gene of Schizosaccharomyces pombe which confers brefeldin A resistance, is structurally related to the ATP-binding cassette superfamily. J Bacteriol 177 (1995) 1536-1543
30. Arioka M., Kouhashi M., Yoda K., Takatsuki A., Yamasaki M., and Kitamoto K. Multidrug resistance phenotype conferred by over-expressing bfr2+/pad1+/sks1+ or pap1+ genes and mediated by bfr1+ gene product, a structural and functional homologue of P-glycoprotein in Schizosaccharomyces pombe. Biosci Biotechnol Biochem 62 (1998) 390-392
31. Shimanuki M., Saka Y., Yanagida M., and Toda T. A novel essential fission yeast gene pad1+ positively regulates pap1+-dependent transcription and is implicated in the maintenance of chromosome structure. J Cell Sci 108 (1995) 569-579
32. Swaffield J.C., Bromberg J.F., and Johnston S.A. Alterations in a yeast protein resembling HIV Tat-binding protein relieve requirement for acidic activation domain in GAL4. Nature 357 (1992) 698-700
33. Akiyama K., Yokota K., Kagawa S., et al. cDNA cloning of a new putative ATPase subunit p45 of the human 26S proteasome, a homolog of yeast transcriptional factor Sug1p. FEBS Lett 363 (1995) 151-156
34. Rubin D.M., Coux O., Wefes I., et al. Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome. Nature 379 (1996) 655-657
35. Wang W., Chevray P.M., and Nathans D. Mammalian Sug1 and c-Fos in the nuclear 26S proteasome. Proc Natl Acad Sci USA 93 (1996) 8236-8240
36. vom Baur E., Zechel C., Heery D., et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J 15 (1996) 110-124
37. Spataro V., Toda T., Craig R., et al. Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26S proteasome subunit. J Biol Chem 272 (1997) 30470-30475
38. Pinkus R., Bergelson S., and Danial V. Phenobarbital induction of AP-1 binding activity mediates activation of glutathione S-transferase and quinine reductase gene expression. Biochem J 290 (1993) 637-640
39. Moffat G.J., McLaren A.W., and Wold C.R. Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells. J Biol Chem 269 (1994) 16397-16402
40. Ritke M.K., Bergoltz V.V., Allan W.P., and Yalowich J.C. Increased c-jun/AP-1 levels in etoposide-resistant human leukaemia K562 cells. Biochem Pharmacol 48 (1994) 525-533
41. Yao K.S., Godwin A.K., Johnson S.W., Ozols R.F., O'Dwyer P.J., and Hamilton T.C. Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55 (1995) 4367-4374
42. Spataro V., Simmen K., and Realini C.A. The essential 26S proteasome subunit Rpn11 confers multidrug resistance to mammalian cells. Anticancer Res 22 (2002) 3905-3910
43. Hirao A., Cheung A., Duncan G., et al. Chk2 is a tumour suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 22 (2002) 6521-6532
44. Zhang P., Gao W., Li H., Reed E., and Chen F. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells. Biochem Biophys Res Commun 328 (2005) 567-572
45. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
46. Li B., and Dou Q.P. Bax degradation by the ubiquitin/proteasome pathway: involvement in tumour survival and progression. Proc Natl Acad Sci USA 97 (2000) 3850-3855
47. Marshansky V., Wang X., Bertrand R., et al. Proteasomes modulate balance among pro-apoptotic and anti apoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 166 (2001) 3130-3142
48. Breitschopf K., Zeiher A.M., and Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 275 (2000) 21648-21652
49. Huang H., Joazeiro C.A., Bonfocco E., Kamada S., Leverson J.D., and Hunter T. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem 275 (2000) 26661-26664
50. Suzuki Y., Nakabayashi Y., and Takahashi R. Ubiquitin-protein ligase activity of x-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect if Fas-induced cell death. Proc Natl Acad Sci USA 98 (2001) 8662-8667
51. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18 (2000) 621-663
52. Munshi A., Kurland J.F., Nishikawa T., Chiao P.J., Andreeff M., and Meyn R.E. Inhibition of constitutively activated nuclear factor-κB radiosensitizes human melanoma cells. Mol Cancer Ther 3 (2004) 985-992
53. Taylor R.C., Adrian C., and Martin S.J. Proteases, proteasomes and apoptosis: breaking Ub is hard to do. Cell Death Differ 12 (2005) 1213-1217
54. Jelinsky S.A., Estep P., Church G.M., and Samson L.D. Regulatory networks revealed by transcriptional profiling of damaged Saccharomyces cerevisiae cells: Rpn4 links with base excision repair with proteasomes. Mol Cell Biol 20 (2000) 8157-8167
55. Ikehata H., Kaneda S., Yamao F., Seno T., Ono T., and Hanaoka F. Incubation at the nonpermissive temperature induces deficiencies in UV resistance and mutagenesis in mouse mutant cells expressing a temperature-sensitive ubiquitin-activating enzyme (E1). Mol Cell Biol 17 (1997) 1484-1489
56. Jentsch S., McGrath J.P., and Varshavsky A. The yeast DNA repair gene RAD6 encodes a ubiquitin-conjugating enzyme. Nature 329 (1987) 131-134
57. Chauhan D., Li G., Hideshima T., et al. Blockade of the ubiquitin-conjugating enzyme CDC34 enhances anti myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene 23 (2004) 3597-3602
58. Suzuki A., Toi M., Yamamoto Y., Saji S., Muta M., and Tominaga T. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 89 (1998) 221-227
59. Sjostrom J., Blomqvist C., Heikkila P., et al. Predictive value of p53, mdm-2, p21 and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6 (2000) 3103-3110
60. Wang H., Oliver P., Zhang Z., Agrawal S., and Zhang R. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 1002 (2003) 217-235
61. Kojima K., Konopleva M., McQueen T., O'Brien S., Plunkett W., and Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukaemia. Blood 108 (2006) 993-1000
62. Yu Y., Sun P., Sun L.C., et al. Downregulation of MDM2 expression by RNAi inhibits LoVo human colorectal adenocarcinoma cells growth and the treatment of LoVo cells with mdm2siRNA3 enhances sensitivity to cisplatin. Biochem Biophys Res Commun 339 (2006) 71-78
63. Li M., Brooks C.L., Kon N., and Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13 (2004) 879-886
64. McCusker J.H., and Haber J.E. Cycloheximide-resistant temperature-sensitive lethal mutations of Saccharomyces cerevisiae. Genetics 119 (1988) 305-315
65. Gerlinger U.M., Guckel R., Hoffmann M., Wolf D.H., and Hilt W. Yeast cycloheximide-resistant crl mutants are proteasome mutants defective in protein degradation. Mol Biol Cell 8 (1997) 2487-2499
66. Gordon C., McGurk G., Dillon P., Rosen C., and Hastie N.D. Defective mitosis due to a mutation in the gene for a fission yeast 26S protease subunit. Nature 366 (1993) 355-357
67. Penney M., Wilkinson C., Wallace M., et al. The pad1+ gene encodes a subunit of the 26S proteasome in fission yeast. J Biol Chem 272 (1998) 23938-23945
68. Dubiel W., Ferrell K., and Rechsteiner M. Subunits of the regulatory complex of the 26S protease. Mol Biol Rep 21 (1995) 27-34
69. Goldberg A.L., and Rock K.L. Proteolysis, proteasomes and antigen presentation. Nature 357 (1992) 375-379
70. Xu X., Leo C., Jang Y., et al. Dominant effector genetics in mammalian cells. Nat Genet 27 (2001) 23-29
71. Kawazoe Y., Nakai A., Tanabe M., and Nagata K. Proteasome inhibition leads to the activation of all members of the heat shock factor family. Eur J Biochem 255 (1998) 356-362
72. Kim S.H., Hur W.Y., Kang C.D., Lim Y.S., Kim D.W., and Chung B.S. Involvement of heat shock factor in regulating transcriptional activation of MDR1 gene in multidrug resistant cells. Cancer Lett 115 (1997) 9-14
73. Zhong Q., Gao W., Du F., and Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121 (2005) 1085-1095
74. Kucharczak J.F., Simmons M.J., Duckett C.S., and Gelinas C. Constitutive proteasome-mediated turnover of Bfl-1/A1 and its processing in response to TNF receptor activation in FL512 pro-B cells convert it into a prodeath factor. Cell Death Differ 12 (2005) 1225-1239
75. Smith L, Welham KJ, Watson MB, Drew PJ, Lind MJ, Cawkwell L. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res, in press.